Literature DB >> 1947515

Analysis of clinical trials by treatment actually received: is it really an option?

Y J Lee1, J H Ellenberg, D G Hirtz, K B Nelson.   

Abstract

The primary analysis of a randomized clinical trial should compare patients in their randomly assigned treatment groups (intention to treat analysis). When a substantial number of subjects fail to take a prescribed medication or are switched to a different study medication, it is tempting to consider treatment comparisons using only those subjects with treatment as actually received rather than as prescribed. There are several arguments against this approach: the prognostic balance brought about by randomization is likely to be disturbed; sample size will be reduced; and the validity of the statistical test procedures will be undermined. Further, results of analysis by treatment actually received may suffer from a bias introduced by using compliance, a factor often related to outcome independently of the treatment received, to determine the groups for comparison. The extent and nature of this bias will be related to the definition of compliance in an as treated analysis, a definition which could be unintentionally self-serving. We have investigated the problem of the definition of actual treatment in the context of a recent clinical trial. We used several definitions to classify patients as having received or not received treatment as prescribed. These definitions, when used in as treated analyses, provided results that were at times inconsistent or counter-intuitive, and which neither helped to confirm nor further explain the intention to treat analysis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1947515     DOI: 10.1002/sim.4780101011

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  36 in total

1.  Follow up studies in rheumatoid arthritis.

Authors:  R Landewé; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  David Moher; Kenneth F Schulz; Douglas G Altman
Journal:  Clin Oral Investig       Date:  2003-01-31       Impact factor: 3.573

Review 3.  Is intent-to-treat analysis always (ever) enough?

Authors:  Lewis B Sheiner
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

4.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

Review 5.  [CONSORT statement. Revised findings on quality improvement based on reports from randomized studies in parallel design].

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Schmerz       Date:  2005-04       Impact factor: 1.107

6.  Standards of reporting of randomized controlled trials in general surgery: can we do better?

Authors:  Sabapathy P Balasubramanian; Martin Wiener; Zeiad Alshameeri; Ravindranath Tiruvoipati; Diana Elbourne; Malcolm W Reed
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

Review 7.  Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis.

Authors:  Dean Fergusson; Shawn D Aaron; Gordon Guyatt; Paul Hébert
Journal:  BMJ       Date:  2002-09-21

8.  CMAJ endorses the CONSORT statement. CONsolidation of Standards for Reporting Trials.

Authors:  P Huston; J Hoey
Journal:  CMAJ       Date:  1996-11-01       Impact factor: 8.262

9.  Randomized trial of switching rheumatoid arthritis patients in remission with injectable gold to auranofin.

Authors:  P E Prete; J Zane; M Krailo; M Bulanowski
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

10.  Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?

Authors:  Robert E Becker; Nigel H Greig
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.